Literature DB >> 1712110

A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes.

R W Tindle1, G J Fernando, J C Sterling, I H Frazer.   

Abstract

We have identified a major T-cell epitope, amino acids 48-54 (DRAHYNI, in one-letter code) in the E7 open reading frame protein of human papillomavirus (HPV) type 16. Lymph node cells from mice immunized with synthetic peptides containing DRAHYNI proliferated and produced interleukin when challenged in vitro with peptide or whole HPV-16 E7 fusion protein. The T epitope was recognized in association with all five major histocompatibility complex class II I-A and I-E alleles tested. Synthetic peptides consisting of DRAHYNI linked to major B-cell epitopes on the E7 molecule formed immunogens capable of eliciting strong antibody responses to HPV-16 E7. The T epitope could provide help for the production of antibody to several B epitopes simultaneously, including a B epitope of HPV-18 E7 protein. Mice immunized with a peptide containing DRAHYNI and B epitope and, at a later date, infected with recombinant vaccinia E7 virus, displayed secondary antibody responses to E7. Because E7 has a role in cell transformation and is the most abundant viral protein in HPV-associated neoplastic cervical epithelial cells, the data have implications for vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712110      PMCID: PMC51983          DOI: 10.1073/pnas.88.13.5887

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  The molecular specificity of linear B-epitopes in the E7 open reading frame protein of human papillomavirus 16 defined by monoclonal antibodies.

Authors:  R W Tindle; W D Zhou; A Saul; I H Frazer
Journal:  Pept Res       Date:  1990 Jul-Aug

2.  Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

Authors:  D R Milich; J L Hughes; A McLachlan; G B Thornton; A Moriarty
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

3.  Induction of rabies virus-specific T-helper cells by synthetic peptides that carry dominant T-helper cell epitopes of the viral ribonucleoprotein.

Authors:  H C Ertl; B Dietzschold; M Gore; L Otvos; J K Larson; W H Wunner; H Koprowski
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  T lymphocyte response to bacteriophage lambda repressor cI protein. Recognition of the same peptide presented by Ia molecules of different haplotypes.

Authors:  M Z Lai; D T Ross; J G Guillet; T J Briner; M L Gefter; J A Smith
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

5.  Identification and characterization of T helper epitopes in the nucleoprotein of influenza A virus.

Authors:  X M Gao; F Y Liew; J P Tite
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

6.  Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells.

Authors:  S Yasumoto; A L Burkhardt; J Doniger; J A DiPaolo
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

7.  Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein.

Authors:  R W Tindle; J A Smith; H M Geysen; L A Selvey; I H Frazer
Journal:  J Gen Virol       Date:  1990-06       Impact factor: 3.891

8.  Analysis of the L1 gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant.

Authors:  H M Browne; M J Churcher; M A Stanley; G L Smith; A C Minson
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

9.  Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells.

Authors:  G Matlashewski; J Schneider; L Banks; N Jones; A Murray; L Crawford
Journal:  EMBO J       Date:  1987-06       Impact factor: 11.598

10.  Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells.

Authors:  K Seedorf; T Oltersdorf; G Krämmer; W Röwekamp
Journal:  EMBO J       Date:  1987-01       Impact factor: 11.598

View more
  27 in total

Review 1.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

2.  BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.

Authors:  Hyun-Il Cho; Kelly Barrios; Young-Ran Lee; Angelika K Linowski; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2012-12-25       Impact factor: 6.968

3.  Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.

Authors:  D W Liu; Y P Tsao; J T Kung; Y A Ding; H K Sytwu; X Xiao; S L Chen
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen.

Authors:  W F Cheng; C H Hung; C Y Chai; K F Hsu; L He; M Ling; T C Wu
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.

Authors:  Qi Zeng; Shiwen Peng; Archana Monie; Ming Yang; Xiaowu Pang; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2011-03-09       Impact factor: 5.695

6.  Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.

Authors:  A Lamikanra; Z K Pan; S N Isaacs; T C Wu; Y Paterson
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.

Authors:  J C Steele; T Stankovic; P H Gallimore
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

8.  A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

Authors:  R W Tindle; S Croft; K Herd; K Malcolm; A F Geczy; T Stewart; G J Fernando
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

9.  Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.

Authors:  Yi-Fang Chen; Chih-Wei Lin; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

Authors:  T C Wu; F G Guarnieri; K F Staveley-O'Carroll; R P Viscidi; H I Levitsky; L Hedrick; K R Cho; J T August; D M Pardoll
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.